Legend Biotech (LEGN) Capital Leases (2023 - 2024)
Legend Biotech (LEGN) posted Capital Leases of $45.6 million for Q3 2024, up 3.6% on a QoQ basis from $44.0 million in Q2 2024, and up 209.45% year-over-year from $14.7 million in Q4 2023.
Legend Biotech (LEGN) has 2 years of Capital Leases data on file, last reported at $45.6 million in Q3 2024.
- In Q3 2024, Capital Leases rose 209.45% year-over-year to $45.6 million; the TTM figure through Sep 2024 stood at $45.6 million (up 209.45% YoY), while the FY2023 annual figure was $44.2 million, changed N/A from the prior year.
- Capital Leases rose to $45.6 million in Q3 2024, from $44.0 million in the prior quarter.
- Across five years, Capital Leases topped out at $45.6 million in Q3 2024 and bottomed at -$44.4 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 45.63 Mn |
| Jun 30, 2024 | 44.04 Mn |
| Mar 31, 2024 | 45.17 Mn |
| Dec 31, 2023 | 44.17 Mn |
| Sep 30, 2023 | -41.69 Mn |
| Jun 30, 2023 | -44.44 Mn |